An expert had suggested that we improve access to a new cytomegalovirus (CMV) treatment drug that has shown effect in patients with resistance as CMV has a major impact on transplanted organs.

Sung Shin, Professor of Kidney and Pancreas Transplantation at Asan Medical Center (Director of General Affairs, the Korean Society for Transplantation) expressed so at a meeting with Dailypharm, explaining how Livtencity, which has been shown to be effective in second-line treatment, could be beneficial amid the rising number of CMV patients developing resistance to existing first-line therapies.

CMV is a member of the herpesvirus family that causes infectious diseases. The risk of CMV infection i